<?xml version='1.0' encoding='utf-8'?>
<document id="25264242"><sentence text="Assessment of cytochrome P450-mediated drug-drug interaction potential of orteronel and exposure changes in patients with renal impairment using physiologically based pharmacokinetic modeling and simulation." /><sentence text="Orteronel is a nonsteroidal, selective inhibitor of 17,20-lyase that was recently in phase 3 clinical development as a treatment for castration-resistant prostate cancer" /><sentence text=" In humans, the primary clearance route for orteronel is renal excretion" /><sentence text=" Human liver microsomal studies indicated that orteronel weakly inhibits CYP1A2, 2C8, 2C9 and 2C19, with IC50 values of 17" /><sentence text="8, 27" /><sentence text="7, 30" /><sentence text="8 and 38" /><sentence text="8 µm, respectively, whereas orteronel does not inhibit CYP2B6, 2D6 or 3A4/5 (IC50  &gt; 100 µm)" /><sentence text=" Orteronel also does not exhibit time-dependent inhibition of CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6 or 3A4/5" /><sentence text=" The results of a static model indicated an [I]/Ki ratio &gt;0" /><sentence text="1 for CYP1A2, 2C8, 2C9 and 2C19" /><sentence text=" Therefore, a physiologically based pharmacokinetic (PBPK) model was developed to assess the potential for drug-drug interactions (DDIs) between orteronel and theophylline, repaglinide, (S)-warfarin and omeprazole, which are sensitive substrates of CYP1A2, 2C8, 2C9 and 2C19, respectively"><entity charOffset="159-171" id="DDI-PubMed.25264242.s12.e0" text="theophylline" /><entity charOffset="173-184" id="DDI-PubMed.25264242.s12.e1" text="repaglinide" /><entity charOffset="186-198" id="DDI-PubMed.25264242.s12.e2" text="(S)-warfarin" /><entity charOffset="203-213" id="DDI-PubMed.25264242.s12.e3" text="omeprazole" /><pair ddi="false" e1="DDI-PubMed.25264242.s12.e0" e2="DDI-PubMed.25264242.s12.e0" /><pair ddi="false" e1="DDI-PubMed.25264242.s12.e0" e2="DDI-PubMed.25264242.s12.e1" /><pair ddi="false" e1="DDI-PubMed.25264242.s12.e0" e2="DDI-PubMed.25264242.s12.e2" /><pair ddi="false" e1="DDI-PubMed.25264242.s12.e0" e2="DDI-PubMed.25264242.s12.e3" /><pair ddi="false" e1="DDI-PubMed.25264242.s12.e1" e2="DDI-PubMed.25264242.s12.e1" /><pair ddi="false" e1="DDI-PubMed.25264242.s12.e1" e2="DDI-PubMed.25264242.s12.e2" /><pair ddi="false" e1="DDI-PubMed.25264242.s12.e1" e2="DDI-PubMed.25264242.s12.e3" /><pair ddi="false" e1="DDI-PubMed.25264242.s12.e2" e2="DDI-PubMed.25264242.s12.e2" /><pair ddi="false" e1="DDI-PubMed.25264242.s12.e2" e2="DDI-PubMed.25264242.s12.e3" /></sentence><sentence text=" Simulation of the area under the plasma concentration-time curve (AUC) of these four CYP substrates in the presence and absence of orteronel revealed geometric mean AUC ratios &lt;1" /><sentence text="25" /><sentence text=" Therefore, in accordance with the 2012 US FDA Draft Guidance on DDIs, orteronel can be labeled a 'non-inhibitor' and further clinical DDI evaluation is not required" /><sentence text=" In PBPK models of moderate and severe renal impairment, the AUC of orteronel was predicted to increase by 52% and 83%, respectively" /><sentence text=" These results are in agreement with those of a clinical trial in which AUC increases of 38% and 87% were observed in patients with moderate and severe renal impairment, respectively" /><sentence text="" /></document>